Back

Predictors for non-persistence to edoxaban in Asian patients with atrial fibrillation: 2-year follow-up data from the ETNA-AF programme

12 April 2026 (08:00 - 18:30)
Organised by: Logo
Congress Presentation Part of: Poster session (1): supraventricular arrhythmias Clinical EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Jong-Il Choi

Korea University Medical Center, Seoul (Korea (Republic of))

196 More presentations in this session

Presentation thumbnail
Electrocardiographic differentiation of narrow QRS complex tachycardia: validation of the new aVL and aVR criteria and a unifying approach to ECG analysis
Doctor J. Stec (Cracow, PL)
Abstract Slides Video
Presentation thumbnail
Characterization of paroxysmal atrial fibrillation in atrial septal defects: contribution of a left atrial substrate
Doctor N. Ramdat Misier (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Spatial distribution of effective refractory period in atrial fibrillation patients
Associate Professor A. Loewe (Karlsruhe, DE)
Abstract Slides
Presentation thumbnail
Early onset atrial fibrillation as a marker of inherited cardiomyopathy: lessons from combined imaging and genetic assessment
Doctor V. Rella (Milan, IT)
Abstract Slides Video
Presentation thumbnail
BMI discrepancy and new-onset atrial fibrillation: findings from UK biobank
Doctor J. Choi (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session (1): supraventricular arrhythmias

The Event

Event poster

EHRA 2026

12 April 2026 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Persistence and predictors for non-persistence to edoxaban therapy in patients with atrial fibrillation: 4-year follow-up data from the ETNA-AF-Europe study
thumbnail
Congress Presentation
Impact of renal impairment and other high bleeding risk factors on clinical outcomes among Asian patients with atrial fibrillation on edoxaban: a post hoc analysis of the ETNA-AF program
thumbnail
Congress Presentation
One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation: First snapshot of more than 4,800 patients from the ETNA-AF-China study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources